GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EGEIRO Pharma (XPAR:ALVET) » Definitions » Current Deferred Revenue

EGEIRO Pharma (XPAR:ALVET) Current Deferred Revenue : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is EGEIRO Pharma Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

EGEIRO Pharma's current deferred revenue for the quarter that ended in Dec. 2023 was €0.00 Mil.

EGEIRO Pharma Current Deferred Revenue Historical Data

The historical data trend for EGEIRO Pharma's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EGEIRO Pharma Current Deferred Revenue Chart

EGEIRO Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
- - - - -

EGEIRO Pharma Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

EGEIRO Pharma Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of EGEIRO Pharma's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


EGEIRO Pharma Business Description

Traded in Other Exchanges
N/A
Address
Avenue Jean Mermoz 32/1, Gosselies, BEL, 6041
EGEIRO Pharma is a biopharmaceutical company. The company is focused on the clinical development of drugs for Idiopathic Pulmonary Fibrosis, a chronic, devastating, and fatal disease characterized by the deterioration of lung function.

EGEIRO Pharma Headlines

No Headlines